OncoMatch/Clinical Trials/NCT04199741
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Is NCT04199741 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including 89Zr-DFO-SC16.56 and SC16.56, Phase I, Cohort 2 for small cell lung cancer.
Treatment: 89Zr-DFO-SC16.56 · SC16.56, Phase I, Cohort 2 · SC16.56, Phase I, Cohort 3 · SC16.56, Phase II — The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04199741 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages